This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson’s disease


Witt, Karsten, Daniels, Christine, Krack, Paul, Volkmann, Jens, Pinsker, Markus O., Kloss, Manja, Tronnier, Volker, Schnitzler, Alfons, Wojtecki, Lars, Bötzel, Kai, Danek, Adrian, Hilker, Rüdiger, Sturm, Volker, Kupsch, Andreas, Karner, Elfriede, Deuschl, Günther


Journal Of The Neurological Sciences, Volume: 310, No.: 1-2, Pages.: 261-266

Year of Publication



Deep brain stimulation (DBS) of the subthalamic nucleus (STN) significantly improves quality of life (QoL) in Parkinson’s disease (PD). Dementia is considered as a contraindication for STN-DBS. However, no controlled study assessed the impact of STN-DBS on the QoL and motor outcome in PD patients with a borderline global cognitive impairment. We studied clinical baseline and progression parameters in a cohort of STN-DBS patients with a global cognitive score still in the non-demented range but scoring in the lowest quartile of the Mattis Dementia Rating Scale (MDRS), a measure of global cognitive functioning. Data from a German randomised controlled study comparing DBS (60 patients) with best medical treatment (BMT, 59 patients) were analysed. Changes in patients’ QoL scores were assessed using the Parkinson’s disease questionnaire (PDQ-39) at baseline and at the 6 months follow up. Patients were split into four groups according to their MDRS performance at baseline and these groups were compared in the context of motor outcome and QoL. Twelve out of sixty patients of the STN-DBS group scored in the lowest quartile of the MDRS (range between one hundred thirty and one hundred thirty seven points). An individual analysis revealed that 3 of 12 patients showed a clinical relevant improvement in QoL whereas the group statistics did not reveal any significant improvement in QoL measures after STN-DBS compared to the BMT group. Since this failure to improve in QoL cannot be explained by a failure to improve in motor functions, stimulation settings and psychiatric scales after STN-DBS, the failure to improve in QoL in patients with a borderline global cognitive score might be specifically related to lower cognitive functioning.; Copyright © 2011 Elsevier B.V. All rights reserved.

Bibtex Citation

@article{Witt_2011, doi = {10.1016/j.jns.2011.06.028}, url = {}, year = 2011, month = {nov}, publisher = {Elsevier {BV}}, volume = {310}, number = {1-2}, pages = {261--266}, author = {Karsten Witt and Christine Daniels and Paul Krack and Jens Volkmann and Markus O. Pinsker and Manja Kloss and Volker Tronnier and Alfons Schnitzler and Lars Wojtecki and Kai Bötzel and Adrian Danek and Rüdiger Hilker and Volker Sturm and Andreas Kupsch and Elfriede Karner and Günther Deuschl}, title = {Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson{textquotesingle}s disease}, journal = {Journal of the Neurological Sciences} }


adverse effects, aged, brain, cognition disorders, deep, deep brain stimulation, diagnosis, etiology, female, humans, male, middle aged, neuropsychological tests, outcome assessment (health care), parkinson disease, physiology, quality of life, questionnaires, reproducibility of results, stimulation, subthalamic nucleus, therapy

Countries of Study


Types of Dementia

Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes

Quality of Life of Person With Dementia

Type of Interventions

Non-pharmacological Treatment

Non-Pharmaceutical Interventions